{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T19:05:38Z","timestamp":1775675138228,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"DOI":"10.1007\/s13577-026-01374-4","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T17:10:15Z","timestamp":1775668215000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pathological and therapeutic implications of Notch overexpression in claudin-low breast cancers"],"prefix":"10.1007","volume":"39","author":[{"given":"Reena","family":"Yadav","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumit","family":"Goel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepinder","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laxmi","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divya","family":"Dahiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanjit","family":"Bal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7976-0824","authenticated-orcid":false,"given":"Alka","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"issue":"1","key":"1374_CR1","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1038\/s41467-020-15574-5","volume":"11","author":"C Fougner","year":"2020","unstructured":"Fougner C, et al. Re-definition of claudin-low as a breast cancer phenotype. Nat Commun. 2020;11(1):1787.","journal-title":"Nat Commun"},{"issue":"10","key":"1374_CR2","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.3390\/cancers15102689","volume":"15","author":"IA Voutsadakis","year":"2023","unstructured":"Voutsadakis IA. Comparison of clinical subtypes of breast cancer within the claudin-low molecular cluster reveals distinct phenotypes. Cancers(Basel). 2023;15(10):2689.","journal-title":"Cancers (Basel)"},{"key":"1374_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1226118","volume":"13","author":"C Pan","year":"2023","unstructured":"Pan C, et al. Research progress of claudin-low breast cancer. Front Oncol. 2023;13:1226118.","journal-title":"Front Oncol"},{"key":"1374_CR4","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94296","author":"C Dominguez","year":"2017","unstructured":"Dominguez C, et al. Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer. JCI Insight. 2017. https:\/\/doi.org\/10.1172\/jci.insight.94296.","journal-title":"JCI Insight"},{"issue":"49","key":"1374_CR5","doi-asserted-by":"publisher","first-page":"5997","DOI":"10.1038\/onc.2015.48","volume":"34","author":"J Knezevic","year":"2015","unstructured":"Knezevic J, et al. Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential. Oncogene. 2015;34(49):5997\u20136006.","journal-title":"Oncogene"},{"issue":"1","key":"1374_CR6","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1038\/s41467-021-23957-5","volume":"12","author":"PD R\u00e4dler","year":"2021","unstructured":"R\u00e4dler PD, et al. Highly metastatic claudin-low mammary cancers can originate from luminal epithelial cells. Nat Commun. 2021;12(1):3742.","journal-title":"Nat Commun"},{"issue":"1","key":"1374_CR7","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1038\/s41467-020-17249-7","volume":"11","author":"RM Pommier","year":"2020","unstructured":"Pommier RM, et al. Comprehensive characterization of claudin-low breast tumors reflects the impact of the cell-of-origin on cancer evolution. Nat Commun. 2020;11(1):3431.","journal-title":"Nat Commun"},{"issue":"8","key":"1374_CR8","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.clbc.2022.09.001","volume":"22","author":"R Yadav","year":"2022","unstructured":"Yadav R, et al. Claudins: the newly emerging targets in breast cancer. Clin Breast Cancer. 2022;22(8):737\u201352.","journal-title":"Clin Breast Cancer"},{"issue":"9","key":"1374_CR9","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/onc.2016.289","volume":"36","author":"S Tabari\u00e8s","year":"2017","unstructured":"Tabari\u00e8s S, Siegel PM. The role of claudins in cancer metastasis. Oncogene. 2017;36(9):1176\u201390.","journal-title":"Oncogene"},{"issue":"7","key":"1374_CR10","first-page":"3406","volume":"11","author":"J Li","year":"2021","unstructured":"Li J. Targeting claudins in cancer: diagnosis, prognosis and therapy. Am J Cancer Res. 2021;11(7):3406\u201324.","journal-title":"Am J Cancer Res"},{"key":"1374_CR11","doi-asserted-by":"publisher","first-page":"1051497","DOI":"10.3389\/fonc.2022.1051497","volume":"12","author":"DW Wang","year":"2022","unstructured":"Wang DW, et al. The role and mechanism of claudins in cancer. Front Oncol. 2022;12:1051497.","journal-title":"Front Oncol"},{"issue":"1","key":"1374_CR12","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1186\/s12885-022-10383-z","volume":"22","author":"H Yousefi","year":"2022","unstructured":"Yousefi H, et al. Notch signaling pathway: a comprehensive prognostic and gene expression profile analysis in breast cancer. BMC Cancer. 2022;22(1):1282.","journal-title":"BMC Cancer"},{"issue":"21\u201322","key":"1374_CR13","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1101\/gad.342287.120","volume":"34","author":"A Nandi","year":"2020","unstructured":"Nandi A, Chakrabarti R. The many facets of Notch signaling in breast cancer: toward overcoming therapeutic resistance. Genes Dev. 2020;34(21\u201322):1422\u201338.","journal-title":"Genes Dev"},{"issue":"7","key":"1374_CR14","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.tcb.2018.03.001","volume":"28","author":"A Totaro","year":"2018","unstructured":"Totaro A, et al. Crosstalk between YAP\/TAZ and Notch signaling. Trends Cell Biol. 2018;28(7):560\u201373.","journal-title":"Trends Cell Biol"},{"issue":"7","key":"1374_CR15","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/s41580-025-00835-2","volume":"26","author":"SJ Bray","year":"2025","unstructured":"Bray SJ, Bigas A. Modes of Notch signalling in development and disease. Nat Rev Mol Cell Biol. 2025;26(7):522\u201337.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"1374_CR16","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1021\/acsami.4c16278","volume":"17","author":"Y Liu","year":"2025","unstructured":"Liu Y, et al. Notch pathway deactivation sensitizes breast cancer stem cells toward chemotherapy using NIR light-responsive nanoparticles. ACS Appl Mater Interfaces. 2025;17(1):430\u201344.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"2","key":"1374_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41573-020-00091-3","volume":"20","author":"S Majumder","year":"2021","unstructured":"Majumder S, et al. Targeting Notch in oncology: the path forward. Nat Rev Drug Discov. 2021;20(2):125\u201344.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"1374_CR18","doi-asserted-by":"publisher","first-page":"e608","DOI":"10.1002\/onco.13627","volume":"26","author":"TR McCaw","year":"2021","unstructured":"McCaw TR, et al. Gamma Secretase inhibitors in cancer: a current perspective on clinical performance. Oncologist. 2021;26(4):e608\u201321.","journal-title":"Oncologist"},{"key":"1374_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155502","volume":"261","author":"R Yadav","year":"2024","unstructured":"Yadav R, et al. Comparative morphology of tumour microenvironment in claudin-low and claudin-high breast cancers. Pathol Res Pract. 2024;261:155502.","journal-title":"Pathol Res Pract"},{"issue":"5","key":"1374_CR20","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1158\/0008-5472.CAN-04-2770","volume":"65","author":"S Mima","year":"2005","unstructured":"Mima S, et al. Induction of claudin-4 by nonsteroidal anti-inflammatory drugs and its contribution to their chemopreventive effect. Cancer Res. 2005;65(5):1868\u201376.","journal-title":"Cancer Res"},{"issue":"6","key":"1374_CR21","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.3892\/ol.2015.3135","volume":"9","author":"H Mei","year":"2015","unstructured":"Mei H, et al. Doxorubicin activates the Notch signaling pathway in osteosarcoma. Oncol Lett. 2015;9(6):2905\u20139.","journal-title":"Oncol Lett"},{"issue":"1","key":"1374_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168669","volume":"12","author":"K Dias","year":"2017","unstructured":"Dias K, et al. Claudin-low breast cancer; clinical & pathological characteristics. PLoS ONE. 2017;12(1):e0168669.","journal-title":"PLoS ONE"},{"issue":"8","key":"1374_CR23","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1073\/pnas.1106509108","volume":"109","author":"JM Haughian","year":"2012","unstructured":"Haughian JM, et al. Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proc Natl Acad Sci U S A. 2012;109(8):2742\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1374_CR24","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1158\/1078-0432.CCR-14-1348","volume":"21","author":"K Wang","year":"2015","unstructured":"Wang K, et al. PEST domain mutations in Notch receptors comprise an oncogenic driver segment in Triple-Negative Breast Cancer sensitive to a \u03b3-Secretase inhibitor. Clin Cancer Res. 2015;21(6):1487\u201396.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1374_CR25","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/modpathol.3800785","volume":"20","author":"BC Dickson","year":"2007","unstructured":"Dickson BC, et al. High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol. 2007;20(6):685\u201393.","journal-title":"Mod Pathol"},{"issue":"6","key":"1374_CR26","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/s41419-021-03735-3","volume":"12","author":"Y-Q Zhang","year":"2021","unstructured":"Zhang Y-Q, et al. Notch3 inhibits cell proliferation and tumorigenesis and predicts better prognosis in breast cancer through transactivating PTEN. Cell Death Dis. 2021;12(6):502.","journal-title":"Cell Death Dis"},{"issue":"8","key":"1374_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41389-018-0069-z","volume":"7","author":"H-Y Lin","year":"2018","unstructured":"Lin H-Y, et al. Notch3 inhibits epithelial\u2013mesenchymal transition in breast cancer via a novel mechanism, upregulation of GATA-3 expression. Oncogenesis. 2018;7(8):59.","journal-title":"Oncogenesis"},{"issue":"16","key":"1374_CR28","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.7150\/thno.19989","volume":"7","author":"XW Dou","year":"2017","unstructured":"Dou XW, et al. Notch3 maintains luminal phenotype and suppresses tumorigenesis and metastasis of breast cancer via trans-activating estrogen receptor-\u03b1. Theranostics. 2017;7(16):4041\u201356.","journal-title":"Theranostics"},{"issue":"5","key":"1374_CR29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41389-018-0051-9","volume":"7","author":"G Diluvio","year":"2018","unstructured":"Diluvio G, et al. NOTCH3 inactivation increases triple-negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest. Oncogenesis. 2018;7(5):42.","journal-title":"Oncogenesis"},{"issue":"6","key":"1374_CR30","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1158\/0008-5472.CAN-16-1022","volume":"77","author":"L Choy","year":"2017","unstructured":"Choy L, et al. Constitutive NOTCH3 signaling promotes the growth of basal breast cancers. Cancer Res. 2017;77(6):1439\u201352.","journal-title":"Cancer Res"},{"key":"1374_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cells9102204","author":"M BeLow","year":"2020","unstructured":"BeLow M, Osipo C. Notch signaling in breast cancer: a role in drug resistance. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9102204.","journal-title":"Cells"},{"key":"1374_CR32","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.canlet.2019.07.012","volume":"461","author":"BM Krishna","year":"2019","unstructured":"Krishna BM, et al. Notch signaling in breast cancer: from pathway analysis to therapy. Cancer Lett. 2019;461:123\u201331.","journal-title":"Cancer Lett"},{"key":"1374_CR33","doi-asserted-by":"publisher","first-page":"2415489","DOI":"10.1155\/2018\/2415489","volume":"2018","author":"EN Kontomanolis","year":"2018","unstructured":"Kontomanolis EN, et al. The Notch pathway in breast cancer progression. Sci World J. 2018;2018:2415489.","journal-title":"Sci World J"},{"issue":"1","key":"1374_CR34","doi-asserted-by":"publisher","first-page":"16218","DOI":"10.1038\/s41598-020-72480-y","volume":"10","author":"D Herrera-Rios","year":"2020","unstructured":"Herrera-Rios D, et al. A computational guided, functional validation of a novel therapeutic antibody proposes Notch signaling as a clinical relevant and druggable target in glioma. Sci Rep. 2020;10(1):16218.","journal-title":"Sci Rep"},{"key":"1374_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113142","author":"K Cante-Barrett","year":"2020","unstructured":"Cante-Barrett K, et al. A molecular test for quantifying functional notch signaling pathway activity in human cancer. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12113142.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"1374_CR36","doi-asserted-by":"publisher","first-page":"757","DOI":"10.7150\/jca.22319","volume":"9","author":"X Li","year":"2018","unstructured":"Li X, et al. Upregulation of HES1 promotes cell proliferation and invasion in breast cancer as a prognosis marker and therapy target via the AKT pathway and EMT process. J Cancer. 2018;9(4):757\u201366.","journal-title":"J Cancer"},{"issue":"4","key":"1374_CR37","doi-asserted-by":"publisher","first-page":"6013","DOI":"10.18632\/oncotarget.13451","volume":"8","author":"M Orzechowska","year":"2017","unstructured":"Orzechowska M, J\u0119droszka D, Bednarek AK. Common profiles of Notch signaling differentiate disease-free survival in luminal type A and triple negative breast cancer. Oncotarget. 2017;8(4):6013\u201332.","journal-title":"Oncotarget"},{"issue":"6","key":"1374_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131689","volume":"10","author":"X Yuan","year":"2015","unstructured":"Yuan X, et al. Expression of Notch1 correlates with breast cancer progression and prognosis. PLoS ONE. 2015;10(6):e0131689.","journal-title":"PLoS ONE"},{"issue":"33","key":"1374_CR39","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.1038\/s41388-018-0251-y","volume":"37","author":"A Baker","year":"2018","unstructured":"Baker A, et al. Notch-1-PTEN-ERK1\/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival. Oncogene. 2018;37(33):4489\u2013504.","journal-title":"Oncogene"},{"issue":"6","key":"1374_CR40","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00428-009-0770-6","volume":"454","author":"AA Blanchard","year":"2009","unstructured":"Blanchard AA, et al. Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype. Virchows Arch. 2009;454(6):647\u201356.","journal-title":"Virchows Arch"},{"issue":"4","key":"1374_CR41","doi-asserted-by":"publisher","first-page":"R54","DOI":"10.1186\/bcr3447","volume":"15","author":"V Bol\u00f3s","year":"2013","unstructured":"Bol\u00f3s V, et al. Notch activation stimulates migration of breast cancer cells and promotes tumor growth. Breast Cancer Res. 2013;15(4):R54.","journal-title":"Breast Cancer Res"},{"issue":"4","key":"1374_CR42","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41418-019-0419-1","volume":"27","author":"S Shin","year":"2020","unstructured":"Shin S, et al. Deubiquitylation and stabilization of Notch1 intracellular domain by ubiquitin-specific protease 8 enhance tumorigenesis in breast cancer. Cell Death Differ. 2020;27(4):1341\u201354.","journal-title":"Cell Death Differ"},{"issue":"1","key":"1374_CR43","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-015-0295-3","volume":"14","author":"S Shao","year":"2015","unstructured":"Shao S, et al. Notch1 signaling regulates the epithelial-mesenchymal transition and invasion of breast cancer in a Slug-dependent manner. Mol Cancer. 2015;14(1):28.","journal-title":"Mol Cancer"},{"issue":"8","key":"1374_CR44","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1038\/s41418-020-0505-4","volume":"27","author":"S Mancarella","year":"2020","unstructured":"Mancarella S, et al. Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA\/DLL4\/MMP13 axis. Cell Death Differ. 2020;27(8):2330\u201343.","journal-title":"Cell Death Differ"},{"key":"1374_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12103027","author":"G Paroni","year":"2020","unstructured":"Paroni G, et al. Retinoic acid sensitivity of triple-negative breast cancer cells characterized by constitutive activation of the notch1 pathway: the role of rar\u03b2. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12103027.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1374_CR46","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41421-023-00592-6","volume":"9","author":"S Zhai","year":"2023","unstructured":"Zhai S, et al. A microprotein N1DARP encoded by LINC00261 promotes Notch1 intracellular domain (N1ICD) degradation via disrupting USP10-N1ICD interaction to inhibit chemoresistance in Notch1-hyperactivated pancreatic cancer. Cell Discov. 2023;9(1):95.","journal-title":"Cell Discov"},{"issue":"5","key":"1374_CR47","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00262-004-0613-x","volume":"54","author":"S Offner","year":"2005","unstructured":"Offner S, et al. Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapy. Cancer Immunol Immunother. 2005;54(5):431\u201345.","journal-title":"Cancer Immunol Immunother"},{"key":"1374_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20164016","author":"Y Hashimoto","year":"2019","unstructured":"Hashimoto Y, et al. Potential for tight junction protein\u2013directed drug development using claudin binders and angubindin-1. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20164016.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1374_CR49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s43188-020-00044-3","volume":"37","author":"SM Choi","year":"2021","unstructured":"Choi SM, et al. Celecoxib induces apoptosis through Akt inhibition in 5-fluorouracil-resistant gastric cancer cells. Toxicol Res. 2021;37(1):25\u201333.","journal-title":"Toxicol Res"},{"issue":"T-NANO 2014 Abs","key":"1374_CR50","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/IJN.S124701","volume":"13","author":"S Singh","year":"2018","unstructured":"Singh S. Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells. Int J Nanomedicine. 2018;13(T-NANO 2014 Abs):11\u20133.","journal-title":"Int J Nanomedicine"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-026-01374-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-026-01374-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-026-01374-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T18:02:16Z","timestamp":1775671336000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-026-01374-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["1374"],"URL":"https:\/\/doi.org\/10.1007\/s13577-026-01374-4","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"3 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Ethics Committee of Postgraduate Institute of Medical Education and Research, Chandigarh, India (Date 18.07.2019\/No INT\/IEC\/2019\/001435).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"62"}}